Survival in Elderly Patients Diagnosed With Acute Myeloid Leukemia: A Hospital-Based Study.

Autor:	Mendoza-Urbano DM; Centro de Investigaciones Clinicas (CIC), Fundacion Valle del Lili, Cali, Colombia., Tello-Cajiao ME; Centro de Investigaciones Clinicas (CIC), Fundacion Valle del Lili, Cali, Colombia., Rosales J; Servicio de Hemato-Oncologia, Departamento de Medicina Interna, Fundacion Valle del Lili, Cali, Colombia., Ahumada FE; Servicio de Hemato-Oncologia, Departamento de Medicina Interna, Fundacion Valle del Lili, Cali, Colombia., Parra-Lara LG; Centro de Investigaciones Clinicas (CIC), Fundacion Valle del Lili, Cali, Colombia.; Facultad de Ciencias de la Salud, Universidad Icesi, Cali, Colombia., Arrieta E; Servicio de Hemato-Oncologia, Departamento de Medicina Interna, Fundacion Valle del Lili, Cali, Colombia.
Jazyk:	angličtina
Zdroj:	Journal of hematology [J Hematol] 2023 Feb; Vol. 12 (1), pp. 7-15. Date of Electronic Publication: 2022 Dec 01.
DOI:	10.14740/jh1055
Abstrakt:	Background: Acute myeloid leukemia (AML) is a hematological neoplasm that is more frequent in elderly patients. The objective of this study was to evaluate elderly patients' survival with de novo AML and acute myeloid leukemia myelodysplasia-related (AML-MR), treated with intensive and less-intensive chemotherapy and supportive care. Methods: A retrospective cohort study was conducted in Fundacion Valle del Lili (Cali, Colombia), between 2013 and 2019. We included patients ≥ 60 years old diagnosed with AML. The statistical analysis considered the leukemia type ( de novo vs. myelodysplasia-related) and treatment (intensive chemotherapy regimen, less-intensive chemotherapy regimen, and without chemotherapy). Survival analysis was performed using Kaplan-Meier method and Cox regression models. Results: A total of 53 patients were included (31 de novo and 22 AML-MR). Intensive chemotherapy regimens were more frequent in patients with de novo leukemia (54.8%), and 77.3% of patients with AML-MR received less-intensive regimens. Survival was higher in the chemotherapy group (P = 0.006), but with no difference between chemotherapy modalities. Additionally, patients without chemotherapy were 10 times more likely to die than those who received any regimen, independent of age, sex, Eastern Cooperative Oncology performance status, and Charlson comorbidity index (adjusted hazard ratio (HR) = 11.6, 95% confidence interval (CI) 3.47 - 38.8). Conclusions: Elderly patients with AML had longer survival time when receiving chemotherapy, regardless of the type of regimen. Competing Interests: The authors declare that they have no competing interests. (Copyright 2023, Mendoza-Urbano et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu